Exercise capacity prior to major cancer surgery: A cross‐sectional observational study of the validity of the 6‐minute walk and 30‐second sit‐to‐stand tests
Asia-Pacific Journal of Clinical Oncology · 2024
DOI: 10.1111/ajco.14069 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Grace Butson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiotherapy, The Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Neoplasms, Exercise Tolerance, Exercise Test. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Cardiopulmonary exercise testing (CPET) is the gold standard for measuring exercise capacity, however, it is resource intensive and has limited availability. This study aimed to determine: 1) the association between the 6‐min walk test (6MWT) and the 30‐s sit‐to‐stand test (30STS) with CPET peak oxygen uptake (VO 2peak ) and anaerobic threshold (AT) and 2) 6MWT and 30STS cut points associated with a higher risk of postoperative complications.
Methods
A cross‐sectional study, retrospectively analyzing data collected from a tertiary cancer center over a 23‐month period. Measures included CPET VO 2peak and AT, 6MWT and 30STS test. Correlations were used to characterize relationships between variables. Receiver operating characteristic curve analyses determined 6MWT and 30STS cut points that aligned with CPET variable cut points.
Results
Note that, 156 participants were included. The 6MWT and 30STS displayed moderate correlations with VO 2peak , rho = 0.65, p = 0.01 and rho = 0.52, p < 0.005 respectively. Fair correlations were observed between AT and 6MWT (rho = 0.36, p = 0.01) and 30STS (rho = 0.41, p < 0.005). The optimal cut points to identify VO 2peak < 15 mL/kg/min were 493.5 m on the 6MWT and 12.5 stands on the 30STS test and for AT < 11 mL/kg/min were 506.5 m on the 6MWT and 12.5 stands on the 30STS test.
Conclusion
Both the 6MWT and 30STS test could be used as alternative tools for measuring exercise capacity preoperatively in the cancer setting where CPET is not available. A range of 6MWT and 30STS cut points, according to sensitivity and specificity levels, may be used to evaluate risk of postoperative outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiotherapy, The Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Health Services Research, The Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Physiotherapy, The University of Melbourne, Melbourne, Australia.
- Department of Anesthesia, Perioperative and Pain Medicine, The Peter MacCallum Cancer Centre, Melbourne, Australia.
ORCID-Profile: Grace Butson, Lara Edbrooke, Hilmy Ismail, Linda Denehy
Zitieren
APA
Butson, G., Edbrooke, L., Ismail, H., Denehy, L., & Centre for Prehabilitation and Peri‐operative Care (CPPOC) (2024). Exercise capacity prior to major cancer surgery: A cross‐sectional observational study of the validity of the 6‐minute walk and 30‐second sit‐to‐stand tests. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14069
Vancouver
Butson G, Edbrooke L, Ismail H, Denehy L, Centre for Prehabilitation and Peri‐operative Care (CPPOC). Exercise capacity prior to major cancer surgery: A cross‐sectional observational study of the validity of the 6‐minute walk and 30‐second sit‐to‐stand tests. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.14069
BibTeX
@article{Butson2024,
author = {Butson, Grace and Edbrooke, Lara and Ismail, Hilmy and Denehy, Linda and Centre for Prehabilitation and Peri‐operative Care (CPPOC), Centre for Prehabilitation and Peri‐operative Care (CPPOC)},
title = {Exercise capacity prior to major cancer surgery: A cross‐sectional observational study of the validity of the 6‐minute walk and 30‐second sit‐to‐stand tests},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2024},
doi = {10.1111/ajco.14069}
}
EUVIMED